Back to top
more

QIAGEN (QGEN)

(Real Time Quote from BATS)

$45.14 USD

45.14
93,748

-0.28 (-0.62%)

Updated Aug 12, 2024 11:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Trina Mukherjee headshot

4 Top-Ranked MedTech Stocks to Bet on Heading Into 2021

Grab these four top stocks that have shown tremendous promise despite market volatility due to the pandemic and have the potential to continue their bull run in 2021.

QIAGEN (QGEN) Launches RUO Solution to Explore Immune Response

QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.

Is QIAGEN (QGEN) a Profitable Stock to Pick Right Now ?

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN

QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio

QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.

QIAGEN (QGEN) Launches COVID-19 Antigen Test With Ellume

QIAGEN (QGEN) starts commercializing latest test after filing for FDA emergency use authorization (EUA) for symptomatic patients.

QIAGEN (QGEN) Q3 Earnings Beat Estimates, FY20 Guidance Up

QIAGEN (QGEN) registeres robust revenue growth across geographies and both operating segments in Q3 despite the coronavirus-led economic crisis.

Qiagen (QGEN) Tops Q3 Earnings and Revenue Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 5.46% and 7.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Align's (ALGN) ClinCheck Suite Now Commercially Available

Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.

Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

The Zacks Analyst Blog Highlights: Edwards Lifesciences, QIAGEN, IDEXX, LHC and ResMed

3 MedTech Growth Stocks to Scoop Up Ahead of Q3 Earnings

Here are three growth stocks from the MedTech space that investors can pick ahead of the quarterly releases.

AnaptysBio (ANAB) Jumps: Stock Rises 7.7%

AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

NeoGenomics (NEO) Looks Good: Stock Adds 5.5% in Session

NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus

Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.

Passage Bio (PASG) Looks Good: Stock Adds 5.4% in Session

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Abbott's New Antibody Test Gets FDA's EUA, Test Suite Expands

Abbott's (ABT) latest antibody test is expected to give a clearer picture of the rate of recovery post coronavirus infection.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Bruker Rides on Nano and MALDI Launches Despite Margin Debacle

Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.

Abbott's Data From Interim Clinical Study of ID NOW Positive

Abbott's (ABT) recent data from an interim clinical study on its ID NOW COVID-19 rapid test reflects the test's capacity to deliver effective, consistent and reliable performance.

Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It?

Bio-Rad (BIO) is optimistic about maintaining robust testing portfolio along with strength in its Life Sciences business.